{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T22:19:16Z","timestamp":1777155556331,"version":"3.51.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2021J011368"],"award-info":[{"award-number":["2021J011368"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14166-0","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T18:41:27Z","timestamp":1745260887000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unravelling NK cell subset dynamics and specific gene signatures post-ibrutinib therapy in chronic lymphocytic leukaemia via single-cell transcriptomics"],"prefix":"10.1186","volume":"25","author":[{"given":"Chunlan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianjian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengzhuo","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"14166_CR1","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2023.1946","volume":"329","author":"M Shadman","year":"2023","unstructured":"Shadman M. Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA. 2023;329:918.","journal-title":"JAMA"},{"key":"14166_CR2","doi-asserted-by":"publisher","first-page":"v78","DOI":"10.1093\/annonc\/mdv303","volume":"26","author":"B Eichhorst","year":"2015","unstructured":"Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2015;26:v78-84.","journal-title":"Ann Oncol"},{"key":"14166_CR3","first-page":"69","volume-title":"Chronic Lymphocytic Leukemia","author":"B Eichhorst","year":"2019","unstructured":"Eichhorst B, Hallek M. Guidelines for diagnosis, indications for treatment, response assessment, and supportive management of chronic lymphocytic leukemia: the 2018 update. In: Hallek M, Eichhorst B, Catovsky D, editors. Chronic Lymphocytic Leukemia. Cham: Springer International Publishing; 2019. p. 69\u201377."},{"key":"14166_CR4","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","volume":"381","author":"TD Shanafelt","year":"2019","unstructured":"Shanafelt TD, Wang XV, Kay NE, Hanson CA, O\u2019Brien S, Barrientos J, et al. Ibrutinib-Rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381:432\u201343.","journal-title":"N Engl J Med"},{"key":"14166_CR5","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","volume":"34","author":"JA Burger","year":"2020","unstructured":"Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34:787\u201398.","journal-title":"Leukemia"},{"key":"14166_CR6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S1470-2045(23)00144-4","volume":"24","author":"P Hillmen","year":"2023","unstructured":"Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B, et al. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:535\u201352.","journal-title":"Lancet Oncol"},{"key":"14166_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","volume":"20","author":"C Moreno","year":"2019","unstructured":"Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:43\u201356.","journal-title":"Lancet Oncol"},{"key":"14166_CR8","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1182\/blood.2021014960","volume":"140","author":"TD Shanafelt","year":"2022","unstructured":"Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O\u2019Brien S, Barrientos J, et al. Long-term outcomes for ibrutinib\u2013rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022;140:112\u201320.","journal-title":"Blood"},{"key":"14166_CR9","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425\u201337.","journal-title":"N Engl J Med"},{"key":"14166_CR10","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","volume":"6","author":"PM Barr","year":"2022","unstructured":"Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6:3440\u201350.","journal-title":"Blood Adv"},{"key":"14166_CR11","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.3324\/haematol.2018.192328","volume":"103","author":"PM Barr","year":"2018","unstructured":"Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, et al. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. 2018;103:1502\u201310.","journal-title":"Haematologica"},{"key":"14166_CR12","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","volume":"370","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Furman RR, Liu T-M, Ozer HG, Zapatka M, Ruppert AS, et al. Resistance mechanisms for the Bruton\u2019s Tyrosine Kinase inhibitor ibrutinib. N Engl J Med. 2014;370:2286\u201394.","journal-title":"N Engl J Med"},{"key":"14166_CR13","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/S0140-6736(00)03231-1","volume":"356","author":"K Imai","year":"2000","unstructured":"Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000;356:1795\u20139.","journal-title":"Lancet"},{"key":"14166_CR14","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41590-020-0728-z","volume":"21","author":"T Bald","year":"2020","unstructured":"Bald T, Krummel MF, Smyth MJ, Barry KC. The NK cell-cancer cycle - advances and new challenges in NK cell-based immunotherapies. Nat Immunol. 2020;21:835\u201347.","journal-title":"Nat Immunol"},{"key":"14166_CR15","doi-asserted-by":"publisher","first-page":"e1330235","DOI":"10.1080\/2162402X.2017.1330235","volume":"6","author":"AW MacFarlane","year":"2017","unstructured":"MacFarlane AW, Jillab M, Smith MR, Alpaugh RK, Cole ME, Litwin S, et al. NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors. Oncoimmunology. 2017;6:e1330235.","journal-title":"Oncoimmunology"},{"key":"14166_CR16","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3390\/cancers13020226","volume":"13","author":"T Pazina","year":"2021","unstructured":"Pazina T, MacFarlane AW, Bernabei L, Dulaimi E, Kotcher R, Yam C, et al. Alterations of NK cell phenotype in the disease course of multiple myeloma. Cancers (Basel). 2021;13:226.","journal-title":"Cancers (Basel)"},{"key":"14166_CR17","doi-asserted-by":"publisher","first-page":"1359084","DOI":"10.3389\/fcell.2024.1359084","volume":"12","author":"L Zhang","year":"2024","unstructured":"Zhang L, Peng X, Ma T, Liu J, Yi Z, Bai J, et al. Natural killer cells affect the natural course, drug resistance, and prognosis of multiple myeloma. Front Cell Dev Biol. 2024;12:1359084.","journal-title":"Front Cell Dev Biol."},{"key":"14166_CR18","doi-asserted-by":"publisher","first-page":"4174","DOI":"10.1182\/blood.V128.22.4174.4174","volume":"128","author":"R Dashnamoorthy","year":"2016","unstructured":"Dashnamoorthy R, Beheshti A, Sarkar S, Sabhachandani P, Passero FC, Purvey S, et al. CD19 Target Activated Natural Killer (CD19.TaNK) cellular Therapy: a novel immunotherapeutic approach to the treatment of Non-Hodgkin Lymphoma (NHL). Blood. 2016;128:4174.","journal-title":"Blood."},{"key":"14166_CR19","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41573-022-00413-7","volume":"21","author":"NA Maskalenko","year":"2022","unstructured":"Maskalenko NA, Zhigarev D, Campbell KS. Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders. Nat Rev Drug Discov. 2022;21:559\u201377.","journal-title":"Nat Rev Drug Discov"},{"key":"14166_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18:85\u2013100.","journal-title":"Nat Rev Clin Oncol"},{"key":"14166_CR21","doi-asserted-by":"publisher","first-page":"eabq7599","DOI":"10.1126\/sciadv.abq7599","volume":"9","author":"H Zhu","year":"2023","unstructured":"Zhu H, Chen J, Liu K, Gao L, Wu H, Ma L, et al. Human PBMC scRNA-seq-based aging clocks reveal ribosome to inflammation balance as a single-cell aging hallmark and super longevity. Sci Adv. 2023;9:eabq7599.","journal-title":"Sci Adv."},{"key":"14166_CR22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/gim.2016.81","volume":"19","author":"S Yi","year":"2017","unstructured":"Yi S, Li Z, Zou D, An G, Cui R, Zhong S, et al. Intratumoral genetic heterogeneity and number of cytogenetic aberrations provide additional prognostic significance in chronic lymphocytic leukemia. Genet Med. 2017;19:182\u201391.","journal-title":"Genet Med"},{"key":"14166_CR23","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/leu.2011.125","volume":"25","author":"T Herold","year":"2011","unstructured":"Herold T, Jurinovic V, Metzeler KH, Boulesteix A-L, Bergmann M, Seiler T, et al. An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia. Leukemia. 2011;25:1639\u201345.","journal-title":"Leukemia"},{"key":"14166_CR24","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/j.1365-2648.2007.04315.x","volume":"59","author":"R Easley","year":"2007","unstructured":"Easley R. Harmony: a concept analysis. J Adv Nurs. 2007;59:551\u20136.","journal-title":"J Adv Nurs"},{"key":"14166_CR25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nbt.2859","volume":"32","author":"C Trapnell","year":"2014","unstructured":"Trapnell C, Cacchiarelli D, Grimsby J, Pokharel P, Li S, Morse M, et al. Pseudo-temporal ordering of individual cells reveals dynamics and regulators of cell fate decisions. Nat Biotechnol. 2014;32:381\u20136.","journal-title":"Nat Biotechnol"},{"key":"14166_CR26","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1126\/science.aax0249","volume":"367","author":"GS Gulati","year":"2020","unstructured":"Gulati GS, Sikandar SS, Wesche DJ, Manjunath A, Bharadwaj A, Berger MJ, et al. Single-cell transcriptional diversity is a hallmark of developmental potential. Science. 2020;367:405\u201311.","journal-title":"Science"},{"key":"14166_CR27","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/nmeth.4463","volume":"14","author":"S Aibar","year":"2017","unstructured":"Aibar S, Gonz\u00e1lez-Blas CB, Moerman T, Huynh-Thu VA, Imrichova H, Hulselmans G, et al. SCENIC: Single-cell regulatory network inference and clustering. Nat Methods. 2017;14:1083\u20136.","journal-title":"Nat Methods"},{"key":"14166_CR28","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1186\/s12967-023-04468-x","volume":"21","author":"H Qin","year":"2023","unstructured":"Qin H, Abulaiti A, Maimaiti A, Abulaiti Z, Fan G, Aili Y, et al. Integrated machine learning survival framework develops a prognostic model based on inter-crosstalk definition of mitochondrial function and cell death patterns in a large multicenter cohort for lower-grade glioma. J Transl Med. 2023;21:588.","journal-title":"J Transl Med"},{"key":"14166_CR29","doi-asserted-by":"publisher","first-page":"bab260","DOI":"10.1093\/bib\/bbab260","volume":"22","author":"D Maeser","year":"2021","unstructured":"Maeser D, Gruener RF, Huang RS. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021;22:bab260.","journal-title":"Brief Bioinform."},{"key":"14166_CR30","doi-asserted-by":"publisher","first-page":"e2350635","DOI":"10.1002\/eji.202350635","volume":"54","author":"C Patterson","year":"2024","unstructured":"Patterson C, Hazime KS, Zelenay S, Davis DM. Prostaglandin E\u2082 impacts multiple stages of the natural killer cell antitumor immune response. Eur J Immunol. 2024;54:e2350635.","journal-title":"Eur J Immunol"},{"key":"14166_CR31","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.3389\/fimmu.2018.01859","volume":"9","author":"A Park","year":"2018","unstructured":"Park A, Lee Y, Kim MS, Kang YJ, Park Y-J, Jung H, et al. Prostaglandin E2 secreted by thyroid cancer cells contributes to immune escape through the suppression of Natural Killer (NK) cell cytotoxicity and NK cell differentiation. Front Immunol. 2018;9:1859.","journal-title":"Front Immunol"},{"key":"14166_CR32","first-page":"2810","volume":"109","author":"C Bi","year":"2024","unstructured":"Bi C, Huang Y, Ali R, Wang F, Yang X, Bouska A, et al. MYC overexpression in natural killer cell lymphoma: prognostic and therapeutic implications. Haematologica. 2024;109:2810\u201321.","journal-title":"Haematologica"},{"key":"14166_CR33","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/s41590-019-0388-z","volume":"20","author":"H Dong","year":"2019","unstructured":"Dong H, Adams NM, Xu Y, Cao J, Allan DSJ, Carlyle JR, et al. The IRE1 endoplasmic reticulum stress sensor activates natural killer cell immunity in part by regulating c-Myc. Nat Immunol. 2019;20:865\u201378.","journal-title":"Nat Immunol"},{"key":"14166_CR34","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.cmet.2016.01.011","volume":"23","author":"L Pedersen","year":"2016","unstructured":"Pedersen L, Idorn M, Olofsson GH, Lauenborg B, Nookaew I, Hansen RH, et al. Voluntary Running Suppresses Tumor Growth through Epinephrine- and IL-6-Dependent NK Cell Mobilization and Redistribution. Cell Metab. 2016;23:554\u201362.","journal-title":"Cell Metab"},{"key":"14166_CR35","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.canlet.2008.07.016","volume":"272","author":"C-Y Lin","year":"2008","unstructured":"Lin C-Y, Chuang T-F, Liao K-W, Huang Y-J, Pai C-C, Chu R-M. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity. Cancer Lett. 2008;272:285\u201395.","journal-title":"Cancer Lett"},{"key":"14166_CR36","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1182\/blood.V88.10.3901.bloodjournal88103901","volume":"88","author":"M Cavazzana-Calvo","year":"1996","unstructured":"Cavazzana-Calvo M, Hacein-Bey S, de Saint BG, De Coene C, Selz F, Le Deist F, et al. Role of interleukin-2 (IL-2), IL-7, and IL-15 in natural killer cell differentiation from cord blood hematopoietic progenitor cells and from gamma c transduced severe combined immunodeficiency X1 bone marrow cells. Blood. 1996;88:3901\u20139.","journal-title":"Blood"},{"key":"14166_CR37","doi-asserted-by":"publisher","first-page":"747324","DOI":"10.3389\/fimmu.2021.747324","volume":"12","author":"D Chen","year":"2021","unstructured":"Chen D, Tang T-X, Deng H, Yang X-P, Tang Z-H. Interleukin-7 biology and its effects on immune cells: mediator of generation, differentiation, survival, and homeostasis. Front Immunol. 2021;12:747324.","journal-title":"Front Immunol"},{"key":"14166_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000203709","volume":"96","author":"G Katrinakis","year":"1996","unstructured":"Katrinakis G, Kyriakou D, Papadaki H, Kalokyri I, Markidou F, Eliopoulos GD. Defective Natural Killer Cell Activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but Not of tumour necrosis Factor-\u03b1. Acta Haematol. 1996;96:16\u201323.","journal-title":"Acta Haematol"},{"key":"14166_CR39","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1182\/blood.V63.2.305.305","volume":"63","author":"NE Kay","year":"1984","unstructured":"Kay NE, Zarling JM. Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood. 1984;63:305\u20139.","journal-title":"Blood"},{"key":"14166_CR40","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1365-2567.2011.03521.x","volume":"135","author":"RT Costello","year":"2012","unstructured":"Costello RT, Knoblauch B, Sanchez C, Mercier D, Le Treut T, S\u00e9bahoun G. Expression of natural killer cell activating receptors in patients with chronic lymphocytic leukaemia. Immunology. 2012;135:151\u20137.","journal-title":"Immunology"},{"key":"14166_CR41","doi-asserted-by":"publisher","first-page":"68513","DOI":"10.18632\/oncotarget.12097","volume":"7","author":"HM Parry","year":"2016","unstructured":"Parry HM, Stevens T, Oldreive C, Zadran B, McSkeane T, Rudzki Z, et al. NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma. Oncotarget. 2016;7:68513\u201326.","journal-title":"Oncotarget"},{"key":"14166_CR42","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41375-020-01025-z","volume":"35","author":"L von Wenserski","year":"2021","unstructured":"von Wenserski L, Schulthei\u00df C, Bolz S, Schliffke S, Simnica D, Willscher E, et al. SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2. Leukemia. 2021;35:1073\u201386.","journal-title":"Leukemia"},{"key":"14166_CR43","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1182\/blood-2014-12-618470","volume":"125","author":"Y-Y Yeh","year":"2015","unstructured":"Yeh Y-Y, Ozer HG, Lehman AM, Maddocks K, Yu L, Johnson AJ, et al. Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. Blood. 2015;125:3297\u2013305.","journal-title":"Blood"},{"key":"14166_CR44","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/01.HS9.0000566052.22020.95","volume":"3","author":"M Falay","year":"2019","unstructured":"Falay M, Serdar M, Dagdas S, Pepeler S, Ucar MA, Ozet G. PB1887 the significance of CD43, CD81, CD200, and ROR1 for differential diagnosis of CLL as multicolor flow cytometry. HemaSphere. 2019;3:859.","journal-title":"HemaSphere"},{"key":"14166_CR45","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1182\/blood-2023-185018","volume":"142","author":"YJ Lim","year":"2023","unstructured":"Lim YJ, Duckworth A, Clarke K, Oates M, Gornall M, Kalakonda N, et al. High Dimensional detection of non-malignant B-cells and its clinical implications in patients with Chronic Lymphocytic Leukaemia (CLL) undergoing frontline therapy. Blood. 2023;142:1894.","journal-title":"Blood"},{"key":"14166_CR46","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4161\/auto.26924","volume":"10","author":"E Viry","year":"2014","unstructured":"Viry E, Baginska J, Berchem G, Noman MZ, Medves S, Chouaib S, et al. Autophagic degradation of GZMB\/granzyme B. Autophagy. 2014;10:173\u20135.","journal-title":"Autophagy"},{"key":"14166_CR47","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1182\/blood-2003-08-2765","volume":"103","author":"JJ Zaunders","year":"2004","unstructured":"Zaunders JJ, Dyer WB, Wang B, Munier ML, Miranda-Saksena M, Newton R, et al. Identification of circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection. Blood. 2004;103:2238\u201347.","journal-title":"Blood"},{"key":"14166_CR48","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1073\/pnas.93.2.685","volume":"93","author":"QG Medley","year":"1996","unstructured":"Medley QG, Kedersha N, O\u2019Brien S, Tian Q, Schlossman SF, Streuli M, et al. Characterization of GMP-17, a granule membrane protein that moves to the plasma membrane of natural killer cells following target cell recognition. Proc Natl Acad Sci USA. 1996;93:685\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"14166_CR49","doi-asserted-by":"publisher","first-page":"931630","DOI":"10.3389\/fimmu.2022.931630","volume":"13","author":"EJ Lelliott","year":"2022","unstructured":"Lelliott EJ, Ramsbottom KM, Dowling MR, Shembrey C, Noori T, Kearney CJ, et al. NKG7 enhances CD8+ T cell synapse efficiency to limit inflammation. Front Immunol. 2022;13:931630.","journal-title":"Front Immunol"},{"key":"14166_CR50","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1158\/2326-6066.CIR-21-0539","volume":"10","author":"T Wen","year":"2022","unstructured":"Wen T, Barham W, Li Y, Zhang H, Gicobi JK, Hirdler JB, et al. NKG7 Is a T-cell\u2013intrinsic therapeutic target for improving antitumor cytotoxicity and cancer immunotherapy. Cancer Immunol Res. 2022;10:162\u201381.","journal-title":"Cancer Immunol Res"},{"key":"14166_CR51","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41590-020-0758-6","volume":"21","author":"SS Ng","year":"2020","unstructured":"Ng SS, De Labastida RF, Yan J, Corvino D, Das I, Zhang P, et al. The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation. Nat Immunol. 2020;21:1205\u201318.","journal-title":"Nat Immunol"},{"key":"14166_CR52","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/2326-6066.CIR-20-0649","volume":"10","author":"X-Y Li","year":"2022","unstructured":"Li X-Y, Corvino D, Nowlan B, Aguilera AR, Ng SS, Braun M, et al. NKG7 is required for optimal antitumor T-cell immunity. Cancer Immunol Res. 2022;10:154\u201361.","journal-title":"Cancer Immunol Res"},{"key":"14166_CR53","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jaci.2016.10.047","volume":"140","author":"J Hosokawa","year":"2017","unstructured":"Hosokawa J, Suzuki K, Meguro K, Tanaka S, Maezawa Y, Suto A, et al. I\u03baBNS enhances follicular helper T-cell differentiation and function downstream of ASCl2. J Allergy Clin Immunol. 2017;140:288-291.e8.","journal-title":"J Allergy Clin Immunol"},{"key":"14166_CR54","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nature12910","volume":"507","author":"X Liu","year":"2014","unstructured":"Liu X, Chen X, Zhong B, Wang A, Wang X, Chu F, et al. Transcription factor achaete-scute homologue 2 initiates T follicular helper cell development. Nature. 2014;507:513\u20138.","journal-title":"Nature"},{"key":"14166_CR55","first-page":"3751","volume":"18","author":"Q Zuo","year":"2018","unstructured":"Zuo Q, Wang J, Chen C, Zhang Y, Feng D-X, Zhao R, et al. ASCL2 expression contributes to gastric tumor migration and invasion by downregulating miR223 and inducing EMT. Mol Med Rep. 2018;18:3751\u20139.","journal-title":"Mol Med Rep"},{"key":"14166_CR56","doi-asserted-by":"publisher","first-page":"2105938","DOI":"10.1002\/advs.202105938","volume":"9","author":"L Wang","year":"2022","unstructured":"Wang L, Yuan Y, Wang J, Luo Y, Lan Y, Ge J, et al. ASCL2 maintains stemness phenotype through ATG9B and sensitizes gliomas to autophagy inhibitor. Adv Sci (Weinh). 2022;9:2105938.","journal-title":"Adv Sci (Weinh)"},{"key":"14166_CR57","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.canlet.2018.03.022","volume":"424","author":"S Basu","year":"2018","unstructured":"Basu S, Gavert N, Brabletz T, Ben-Ze\u2019ev A. The intestinal stem cell regulating gene ASCL2 is required for L1-mediated colon cancer progression. Cancer Letters. 2018;424:9\u201318.","journal-title":"Cancer Letters."},{"key":"14166_CR58","first-page":"955","volume":"7","author":"H Xu","year":"2017","unstructured":"Xu H, Zhao X-L, Liu X, Hu X-G, Fu W-J, Li Q, et al. Elevated ASCL2 expression in breast cancer is associated with the poor prognosis of patients. Am J Cancer Res. 2017;7:955\u201361.","journal-title":"Am J Cancer Res"},{"key":"14166_CR59","first-page":"e21021","volume":"14","author":"Y Shibahara","year":"2022","unstructured":"Shibahara Y, Espin-Garcia O, Conner J, Weiss J, Derouet M, Allen J, et al. Intestinal stem cell marker ASCL2 is a novel prognostic predictor in esophageal adenocarcinoma. Cureus. 2022;14:e21021.","journal-title":"Cureus."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14166-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14166-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14166-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T19:02:41Z","timestamp":1745262161000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14166-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14166"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14166-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"3 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical standards outlined in the Declaration of Helsinki and received ethical approval from the Medical Ethics Committee of The First Affiliated Hospital of Xiamen University, with the assigned protocol number SL- 2023 KY083 -\u200901. All participants provided written informed consent prior to their inclusion in the study, ensuring that they were fully aware of the study objectives, procedures, potential risks, and benefits.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"745"}}